Share this video  

ESMO 2023 | RATIONALE-305: tislelizumab + chemo vs placebo +chemo in advanced GC/GEJC

Tania C. Fleitas, MD, PhD, from the University of Valencia, discusses the Phase III RATIONALE-305 (NCT03777657) study at ESMO 2023. The study evaluates the efficacy of tislelizumab plus chemotherapy compared to placebo (PBO) plus chemotherapy as first-line treatment for advanced gastric or gastroesophageal junction cancer. The primary analysis in the intent-to-treat (ITT) population reveals significantly improved overall survival (OS) with tislelizumab plus chemotherapy (15.0 months) compared to PBO plus chemotherapy (12.9 months), with a hazard ratio of 0.80. Grade ≥3 treatment-related adverse events occurred in 53.8% of patients treated with tislelizumab. These results support tislelizumab as a promising therapeutic option for advanced gastric cancer. This interview took place at the European Society for Medical Oncology (ESMO) 2023 Congress in Madrid, Spain.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.